Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

"We are thrilled to welcome Dr. Leyman at a pivotal time for Sutro, as we advance luvelta in two registrationdirected trials in both ovarian cancer and a rare pediatric cancer and continue to leverage our proprietary cellfree technology to pioneer the next generation of ADCs," said Bill Newell, Sutro's Chief Executive Officer. "Dr. Leyman brings a strong track record of successful dealmaking, along with a depth of experience in the sector from her time as a life science investor and as a value creator withi ...